


ETCTN Trials by Disease/Treatment Area: Solid Tumors- Dose Escalation Only (Disease-Specific Expansion)



NOTE: ▼ Limited trial; not open ETCTN-wide

**ETCTN Solid Tumors- Dose Escalation Only (Disease-Specific Expansion)
Trials (Open as of 5/14/2026)**

| Protocol Number | Phase | Protocol Title |
|------------------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10355 | I | A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies |
| 10509 | I | A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors |
| 10579 | I | Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors |
| 10554 | I | Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression |